JW PHARMACEUTICAL
Financials
Valuation Metrics
JW PHARMACEUTICAL's Market Cap is ₩5836B. At end of 2025 it was ₩6166B. Ranked #419 of 2,414 in KR market (top 17%), #271 of 781 on KOSPI (top 35%), #44 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 583.60B KRW | KR#419/2,414 Sec#44/231 |
| Revenue | 820.86B KRW | KR#454/2,414 Sec#20/231 |
| Net Income | 101.28B KRW | KR#249/2,414 Sec#13/231 |
| Total Assets | 605.27B KRW | KR#677/2,414 Sec#37/231 |
| Net Assets | 369.37B KRW | KR#631/2,414 Sec#40/231 |
| Employees | 1,107 | KR#239/2,414 Sec#14/231 |
| Value | ||
| P/E | 5.76x | KR#466/2,414 Sec#20/231 |
| P/B | 1.58x | KR#1,816/2,414 Sec#128/231 |
| PEG | 0.06x | KR#343/2,414 Sec#19/231 |
| P/S | 0.71x | KR#1,187/2,414 Sec#62/231 |
| EV/EBITDA | 5.04x | KR#251/2,414 Sec#5/231 |
| FCF Yield | 14.50% | KR#475/2,414 Sec#15/231 |
| Profitability | ||
| ROE | 27.42% | KR#75/2,414 Sec#6/231 |
| ROA | 16.73% | KR#81/2,414 Sec#7/231 |
| Op. Margin | 13.94% | KR#332/2,414 Sec#31/231 |
| Revenue Growth | 10.50% | KR#874/2,414 Sec#84/231 |
| Earnings Growth | 94.60% | KR#408/2,414 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 63.87% | KR#1,142/2,414 Sec#134/231 |
| Total Debt | 32.10B KRW | KR#1,192/2,414 Sec#89/231 |
| FCF | 84.62B KRW | KR#219/2,414 Sec#13/231 |
| Cash | 39.23B KRW | KR#864/2,414 Sec#55/231 |
| Current Ratio | 1.56x | KR#1,145/2,414 Sec#124/231 |
| Net Debt/EBITDA | -0.06x | KR#589/2,414 Sec#36/231 |
| Dividend | ||
| Div. Yield | 2.66% | KR#749/2,414 Sec#38/231 |
| Div. Growth | 44.44% | KR#272/2,414 Sec#12/231 |
| Performance | ||
| 1Y Return | 10.96% | KR#458/2,414 Sec#28/231 |
| 1M Return | -10.17% | KR#1,724/2,414 Sec#167/231 |
| From 52W High | -38.09% | KR#756/2,414 Sec#46/231 |
| 1Y MDD | -43.66% | KR#716/2,414 Sec#55/231 |
| Trading | ||
| Volume | 43,188 shares | KR#1,351/2,414 Sec#133/231 |
| Trading Value | 1.05B KRW | KR#781/2,414 Sec#77/231 |
| Foreign Own. | 7.34% | KR#607/2,414 Sec#51/231 |
| Per Share | ||
| EPS | 4,217 KRW | KR#249/2,414 Sec#15/231 |
| BPS | 15,380 KRW | KR#686/2,414 Sec#44/231 |
Company Info
The company began as Joseon Choongwae Pharmaceutical Laboratory in 1945, incorporated in 1953, and expanded its business in 2019 by acquiring Vietnamese Euvipharm after listing in 1976. It holds products such as Livalo, Hemlibra, Trupass, Actemra, and the 3rd-generation 3-chamber nutritional infusion Winuf. The company leads the market with its combined novel drug of pitavastatin and ezetimibe. Utilizing the JWAVE platform, it applies AI models across the entire new drug development cycle to reduce time and cost. JW Pharmaceutical is headquartered in Gwacheon, Gyeonggi-do.